Publications

Wikoff DS, Rager JE, Haws LC, Borghoff SJ. 2016. A high dose mode of action for tetrabromobisphenol A-induced uterine adenocarcinomas in Wistar Han rats: A critical evaluation of key events in an adverse outcome pathway framework. Regul Toxicol Pharmacol 77(June):143-159. doi: 10.1016/j.yrtph.2016.01.018. PMID: 26828025.

Edmondson SD, Zhu C, Kar NF, Di Salvo J, Nagabukuro H, Sacre-Salem B, Dingley K, et al. 2016. Discovery of vibegron: A potent and selective beta 3 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem 59(2):609–623; doi: 10.1021/acs.jmedchem.5b01372. PMID: 26709102.

Zhu C, Kar NF, Li B, Costa M, Dingley KH, Di Salvo J, et al. 2016. Discovery of benzamides as potent human β3 adrenergic receptor agonists. Bioorg Med Chem Lett 26(1):55–59; doi: 10.1016/j.bmcl.2015.11.030. PMID: 26590100.

Wilson JE, Kurukulasuriya R, Sinz C, Matthew Lombardo, Kate Bender, Dann Parker, … Dingley K, et al. 2016. Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes. Bioorg Med Chem Lett 26(12):2947–2951; doi: 10.1016/j.bmcl.2016.04.018. PMID: 27240550.

Guo L, Parker DL, Zang Y, Sweis RF, Liu W, Sherer EC, … Dingley KH, et al. 2016. Discovery and optimization of a novel triazole series of GPR142 agonists for the treatment of type 2 diabetes. ACS Med Chem Lett 7 (12):1107–1111; doi: 10.1021/acsmedchemlett.6b00314. PMID: 27994747.

Pierce JS, Ruestow PS, Finley BL. 2016. An updated evaluation of reported no-observed adverse effect levels for chrysotile asbestos for lung cancer and mesothelioma. Crit Rev Toxicol 46(7):561-586; doi: 10.3109/10408444.2016.1150960.

Cowan DM, Maskrey JR, Fung ES, Woods TA, Stabryla LM, Scott PK, Finley BL. 2016. Best-practices approach to determination of blood alcohol concentration (BAC) at specific time points: Combination of ante-mortem alcohol pharmacokinetic modeling and post-mortem alcohol generation and transport considerations. Regul Toxicol Pharmacol 78(July):24–36; doi: 10.1016/j.yrtph.2016.03.020.

Pierce JS, Abelmann A, Finley BL. 2016. Comment on flavoring chemicals in e-cigarettes: Diacetyl, 2,-3-pentanedione, and acetoin in a sample of 51 products, including fruit-, candy-, and cocktail-flavored e-cigarettes. Environ Health Persp 124(6):A100–A101; doi: 10.1289/ehp.1611350.

Sacks NC, Sharma A, Cyr PL, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Outcomes for older patients with acute myeloid leukemia (AML): Multiple hospitalizations and high mortality rates. Value in Health 19(7):A611; doi: 10.1016/j.jval.2016.09.1523.

Alexander DD, Bylsma LC, Elkayam L, Nguyen DL. 2016. Nutritional and health benefits of semi-elemental diets: A comprehensive summary of the literature. World J Gastrointest Pharmacol Ther 7(2):306-319; doi: 10.4292/wjgpt.v7.i2.306. PMID: 27158547.

Scala E, Price C, Day J. 2016. An integrative review of engaging clinical nurses in nursing research. J Nurs Schol 48(4):423–430; doi: 10.1111/jnu.12223.

Hanlon P, Brorby GP, Krishan M. 2016. A risk-based strategy for evaluating mitigation options for processed-formed compounds in food: Workshop proceedings. Int J Toxicol 35(3):358–370; doi: 10.1177/1091581816640. PMID: 27102178.

Paustenbach DJ, Insley AL, Maskrey JR, Bare JL, Unice KM, Conrad VB, Iordanidis L, Reynolds DW, DiNatale KD, Monnot AD. 2016. Analysis of total arsenic content in California wines and comparison to various health risk criteria. Am J Enol Viticult 67(2):179–187; doi: 10.5344/ajev.2015.15041.

Sacks NC, Cabral HJ, Pizer SD, Burgess JF. 2016. Myopic and forward looking behavior in branded oral anti-diabetic consumption: An example from Medicare Part D. Health Econ 26(6):753-764; doi: 10.1002/hec.3355. PMID: 27150938.

Patlewicz GY, Fitzpatrick J. 2016. Current and future perspectives on the development, evaluation and application of in silico approaches for predicting toxicity. Chem Res Toxicol 29(4):438-451; doi: 10.1021/acs.chemrestox.5b00388. PMID: 26686752.

Franzen A, Van Landingham C, Greene T, Plotzke K, Gentry R. 2016. A global human health risk assessment for decamethylcyclopentasiloxane (D₅). Regul Toxicol Pharmacol 74(Sup):S25–S43; doi: 10.1016/j.yrtph.2015.10.023.

Campbell J, Franzen A, Van Landingham C, Lumpkin M, Crowell S, Meredith C, Loccisano A, Gentry R, Clewell H. 2016. Predicting lung dosimetry of inhaled particle-borne benzo(a)pyrene using physiologically based pharmacokinetic modeling. Inhal Toxicol 28(11):520–535; doi: 10.1080/08958378.2016.1214768.

Williams RV, Amberg A, Brigo A, Coquin L, Giddings A, Glowienke S, Greene N, et al. 2016. It’s difficult, but important, to make negative predictions. Regul Toxicol Pharmacol 76(Apr):79-86; doi: 10.1016/j.yrtph.2016.01.008. PMID: 26785392.

Barber C, Cayley A, Hanser T, Harding A, Heghes C, Vessey JD, Werner S,…, Greene N. 2016. Evaluation of a statistics-based Ames mutagenicity QSAR model and interpretation of the results obtained. Regul Toxicol Pharmacol 76(Apr):7-20; doi: 10.1016/j.yrtph.2015.12.006. PMID: 26708083.

Doucette A, Jiang X, Fryzek J, Coalson J, McLaurin K, Ambrose CS. 2016. Trends in respiratory syncytial virus and bronchiolitis hospitalization rates in high-risk infants in a United States nationally representative database, 1997-2012. PLoS One 11(4):e0152208; doi: 10.1371/journal.pone.0152208. PMID: 27050095.